Oxaliplatin induces immunogenic cell death in hepatocellular carcinoma cells and synergizes with immune checkpoint blockade therapy

R.L. Siegel, K.D. Miller, A. Jemal, Cancer statistics, 2018. CA Cancer J Clin 68, 7–30 (2018)

H.B. El-Serag, Hepatocellular Carcinoma New Engl J Med 365, 1118–1127 (2011)

L.-Y. Wang, S.-S. Zheng, Advances in predicting the prognosis of hepatocellular carcinoma recipients after liver transplantation. J Zhejiang Univ Sci B 19, 497–504 (2018)

S. Lin, K. Hoffmann, P. Schemmer, Treatment of hepatocellular carcinoma: A systematic review. Liver Cancer 1, 144–158 (2012)

H.B. El-Serag, J.A. Marrero, L. Rudolph, K.R. Reddy, Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology 134, 1752–1763 (2008)

J.A. Davila, Duan Z, McGlynn KA, El-Serag HB, Utilization and outcomes of palliative therapy for hepatocellular carcinoma: a population-based study in the United States. J Clin Gastroenterol 46, 71–77 (2012)

H.P. Clark, W.F. Carson, P.V. Kavanagh, C.P. Ho, P. Shen, R.J. Zagoria, Staging and current treatment of hepatocellular carcinoma. Radiographics 25, S3–S23 (2005)

B.A. Seinstra, O.M. van Delden, K.J. van Erpecum, R. van Hillegersberg, W.P.T.M. Mali, M.A.A.J. van den Bosch, Minimally invasive image-guided therapy for inoperable hepatocellular carcinoma: What is the evidence today? Insights Imaging 1, 167–181 (2010)

R. CABRERA, D.R. NELSON, Review article: The management of hepatocellular carcinoma. Aliment Pharmacol Ther 31, 461–476 (2010)

A.X. Zhu, L.S. Blaszkowsky, D.P. Ryan, J.W. Clark, A. Muzikansky, K. Horgan, S. Sheehan, K.E. Hale, P.C. Enzinger, P. Bhargava, K. Stuart, Phase II study of gemcitabine and Oxaliplatin in combination with Bevacizumab in patients with advanced hepatocellular carcinoma. J Clin Oncol 24, 1898–1903 (2006)

S. Singh, P.P. Singh, L.R. Roberts, W. Sanchez, Chemopreventive strategies in hepatocellular carcinoma. Nat Rev Gastro Hepat 11, 45–54 (2014)

E.L. Yoon, J.E. Yeon, H.J. Lee, S.J. Suh, S.J. Lee, S.H. Kang, K. Kang, Y.J. Yoo, J.H. Kim, H.J. Yim, K.S. Byun, Systemic cytotoxic chemotherapy of patients with advanced hepatocellular carcinoma in the era of sorafenib nonavailability. J Clin Gastroenterol 48, e22–e29 (2014)

H. CAO, H. Phan, L.-X. Yang, Improved chemotherapy for hepatocellular carcinoma. Anticancer Res 32, 1379–1386 (2012)

A.D. Garg, S. More, N. Rufo, O. Mece, M.L. Sassano, P. Agostinis, L. Zitvogel, G. Kroemer, L. Galluzzi, Trial watch: Immunogenic cell death induction by anticancer chemotherapeutics. Oncoimmunology 6, e1386829 (2017)

A. Serrano-del Valle, A. Anel, J. Naval, I. Marzo, Immunogenic cell death and immunotherapy of multiple myeloma. Front Cell Dev Biol 7, 149 (2019)

G. Kroemer, L. Galluzzi, O. Kepp, L. Zitvogel, Immunogenic cell death in cancer therapy. Annu Rev Immunol 31, 51–72 (2013)

W. Wang, J. Li, K. Wu, B. Azhati, M. Rexiati, Culture and identification of mouse bone marrow-derived dendritic cells and their capability to induce T lymphocyte proliferation. Med Sci Monitor 22, 244–250 (2016)

Y. Zhai, H. Xie, H. Gu, Effects of hyperthermia with dextran magnetic fluid on the growth of grafted H22 tumor in mice. Int J Hyperth 25, 65–71 (2009)

A. Tesniere, F. Schlemmer, V. Boige, O. Kepp, I. Martins, F. Ghiringhelli, L. Aymeric, M. Michaud, L. Apetoh, L. Barault, J. Mendiboure, J.P. Pignon, V. Jooste, P. van Endert, M. Ducreux, L. Zitvogel, F. Piard, G. Kroemer, Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene 29, 482–491 (2010)

X. Zhao, K. Yang, R. Zhao, T. Ji, X. Wang, X. Yang, Y. Zhang, K. Cheng, S. Liu, J. Hao, H. Ren, K.W. Leong, G. Nie, Inducing enhanced immunogenic cell death with nanocarrier-based drug delivery systems for pancreatic cancer therapy. Biomaterials 102, 187–197 (2016)

E.Y. Chiang, I. Stroynowski, Protective immunity against disparate tumors is mediated by a nonpolymorphic MHC class I molecule. J Immunol 174, 5367–5374 (2005)

U. Singh, Y. Cui, N. Dimaano, S. Mehta, S. Pruitt, J. Yearley, O.F. Laterza, J.W. Juco, B. Dogdas, Analytical validation of quantitative immunohistochemical assays of tumor infiltrating lymphocyte biomarkers. Biotech Histochem 93, 411–423 (2018)

C. Burz, I.B. Berindan-Neagoe, O. Balacescu, C. Tanaselia, M. Ursu, A. Gog, et al., Clinical and pharmacokinetics study of oxaliplatin in colon cancer patients. J Gastrointest Liver 18, 39–43 (2009)

R. Zappasodi, S.M. Pupa, G.C. Ghedini, I. Bongarzone, M. Magni, A.D. Cabras, M.P. Colombo, C. Carlo-Stella, A.M. Gianni, M. di Nicola, Improved clinical outcome in indolent B-cell lymphoma patients vaccinated with autologous tumor cells experiencing immunogenic death. Cancer Res 70, 9062–9072 (2010)

B. Montico, A. Nigro, V. Casolaro, J. Dal Col, Immunogenic apoptosis as a novel tool for anticancer vaccine development. Int J Mol Sci 19, 594 (2018)

D.G. DeNardo, D.J. Brennan, E. Rexhepaj, B. Ruffell, S.L. Shiao, S.F. Madden, et al., Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov 1, 54–67 (2011)

C. Denkert, S. Loibl, A. Noske, M. Roller, B. Muller, M. Komor, et al., Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 28, 105–113 (2010)

N. Halama, S. Michel, M. Kloor, I. Zoernig, A. Benner, A. Spille, T. Pommerencke, D.M. von Knebel, G. Folprecht, B. Luber, N. Feyen, U.M. Martens, P. Beckhove, S. Gnjatic, P. Schirmacher, E. Herpel, J. Weitz, N. Grabe, D. Jaeger, Localization and density of immune cells in the invasive margin of human colorectal cancer liver metastases are prognostic for response to chemotherapy. Cancer Res 71, 5670–5677 (2011)

T. Panaretakis, O. Kepp, U. Brockmeier, A. Tesniere, A.C. Bjorklund, D.C. Chapman, M. Durchschlag, N. Joza, G. Pierron, P. van Endert, J. Yuan, L. Zitvogel, F. Madeo, D.B. Williams, G. Kroemer, Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death. EMBO J 28, 578–590 (2009)

S.J. Gardai, K.A. McPhillips, S.C. Frasch, W.J. Janssen, A. Starefeldt, J.E. Murphy-Ullrich, et al., Cell-surface calreticulin initiates clearance of viable or apoptotic cells through trans-activation of LRP on the phagocyte. Cell 123, 321–334 (2005)

M.R. Elliott, F.B. Chekeni, P.C. Trampont, E.R. Lazarowski, A. Kadl, S.F. Walk, D. Park, R.I. Woodson, M. Ostankovich, P. Sharma, J.J. Lysiak, T.K. Harden, N. Leitinger, K.S. Ravichandran, Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance. Nature 461, 282–286 (2009)

P. Scaffidi, T. Misteli, M.E. Bianchi, Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 418, 191–195 (2002)

D. Tang, R. Kang, K.M. Livesey, G. Kroemer, T.R. Billiar, B. Van Houten, et al., High-mobility group box 1 is essential for mitochondrial quality control. Cell Metab 13, 701–711 (2011)

S.L. Topalian, F.S. Hodi, J.R. Brahmer, S.N. Gettinger, D.C. Smith, D.F. McDermott, et al., Safety, activity, and immune correlates of anti–PD-1 antibody in cancer. New Engl J Med 366, 2443–2454 (2012)

W.H. Fridman, F. Pages, C. Sautes-Fridman, J. Galon, The immune contexture in human tumours: Impact on clinical outcome. Nat Rev Cancer 12, 298–306 (2012)

Rooney MS, Shukla SA, Wu CJ, Getz G, Hacohen N, Molecular and genetic properties of tumors associated with local immune cytolytic activity Cell 160, 48–61 (2015)

P. Sharma, J.P. Allison, The future of immune checkpoint therapy. Science 348, 56–61 (2015)

J.A. Seidel, A. Otsuka, K. Kabashima, Anti-PD-1 and anti-CTLA-4 therapies in Cancer: Mechanisms of action, efficacy, and limitations. Front Oncol 8, 86–86 (2018)

M. Santarpia, M. González-Cao, S. Viteri, N. Karachaliou, G. Altavilla, R. Rosell, Programmed cell death protein-1/programmed cell death ligand-1 pathway inhibition and predictive biomarkers: Understanding transforming growth factor-beta role. Transl Lung Cancer Res 4, 728–742 (2015)

Y. Dong, Q. Sun, X. Zhang, PD-1 and its ligands are important immune checkpoints in cancer. Oncotarget 8, 2171–2186 (2017)

X.Y. Ni, H.X. Sui, Y. Liu, S.Z. Ke, Y.N. Wang, F.G. Gao, TGF-β of lung cancer microenvironment upregulates B7H1 and GITRL expression in dendritic cells and is associated with regulatory T cell generation. Oncol Rep 28, 615–621 (2012)

S. Mariathasan, S.J. Turley, D. Nickles, A. Castiglioni, K. Yuen, Y. Wang, E.E. Kadel III, H. Koeppen, J.L. Astarita, R. Cubas, S. Jhunjhunwala, R. Banchereau, Y. Yang, Y. Guan, C. Chalouni, J. Ziai, Y. Şenbabaoğlu, S. Santoro, D. Sheinson, J. Hung, J.M. Giltnane, A.A. Pierce, K. Mesh, S. Lianoglou, J. Riegler, R.A.D. Carano, P. Eriksson, M. Höglund, L. Somarriba, D.L. Halligan, M.S. van der Heijden, Y. Loriot, J.E. Rosenberg, L. Fong, I. Mellman, D.S. Chen, M. Green, C. Derleth, G.D. Fine, P.S. Hegde, R. Bourgon, T. Powles, TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature 554, 544–548 (2018)

F. Heindryckx, I. Colle, H. Van Vlierberghe, Experimental mouse models for hepatocellular carcinoma research. Int J Exp Pathol 90, 367–386 (2009)